Last reviewed · How we verify
CombiflexOmega peri
CombiflexOmega peri is a Small molecule drug developed by JW Life Science. It is currently in Phase 3 development.
CombiflexOmega peri is an investigational combination therapy designed to modulate inflammatory and metabolic pathways, likely combining omega-3 fatty acid derivatives with additional bioactive compounds for perioperative or chronic inflammatory conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CombiflexOmega peri |
|---|---|
| Sponsor | JW Life Science |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The drug name suggests a combination approach leveraging omega-3 polyunsaturated fatty acids (known for anti-inflammatory properties) with additional agents. The 'peri' designation may indicate perioperative use or peripheral tissue targeting. The exact mechanism remains proprietary and undisclosed in public literature, as this is a Phase 3 investigational agent.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CombiflexOmega peri CI brief — competitive landscape report
- CombiflexOmega peri updates RSS · CI watch RSS
- JW Life Science portfolio CI
Frequently asked questions about CombiflexOmega peri
What is CombiflexOmega peri?
How does CombiflexOmega peri work?
Who makes CombiflexOmega peri?
What development phase is CombiflexOmega peri in?
Related
- Manufacturer: JW Life Science — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing